Skip to main content

Peer Review reports

From: Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease

Original Submission
11 Aug 2021 Submitted Original manuscript
29 Sep 2021 Author responded Author comments - Sandra Neumann
Resubmission - Version 2
29 Sep 2021 Submitted Manuscript version 2
4 Oct 2021 Editorially accepted
29 Oct 2021 Article published 10.1186/s12883-021-02430-2

You can find further information about peer review here.

Back to article page